Center for Nanomedicine, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, United States.
Center for Nanomedicine, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, United States; The Danish National Research Foundation and Villum Foundation's Center for Intelligent Drug Delivery and Sensing Using Microcontainers and Nanomechanics (IDUN), Department of Health Technology, Technical University of Denmark, 2800 Kgs. Lyngby, Denmark.
Adv Drug Deliv Rev. 2023 Dec;203:115116. doi: 10.1016/j.addr.2023.115116. Epub 2023 Oct 21.
Upon entering the biological milieu, nanomedicines swiftly interact with the surrounding tissue fluid, subsequently being enveloped by a dynamic interplay of biomacromolecules, such as carbohydrates, nucleic acids, and cellular metabolites, but with predominant serum proteins within the biological corona. A notable consequence of the protein corona phenomenon is the unintentional loss of targeting ligands initially designed to direct nanomedicines toward particular cells or organs within the in vivo environment. mRNA nanomedicine displays high demand for specific cell and tissue-targeted delivery to effectively transport mRNA molecules into target cells, where they can exert their therapeutic effects with utmost efficacy. In this review, focusing on the delivery systems and tissue-specific applications, we aim to update the nanomedicine population with the prevailing and still enigmatic paradigm of nano-bio interactions, a formidable hurdle in the pursuit of targeted mRNA delivery. We also elucidate the current impediments faced in mRNA therapeutics and, by contemplating prospective avenues-either to modulate the corona or to adopt an 'ally from adversary' approach-aim to chart a course for advancing mRNA nanomedicine.
进入生物环境后,纳米药物迅速与周围组织液相互作用,随后被生物大分子(如碳水化合物、核酸和细胞代谢物)的动态相互作用所包围,但在生物冠层中主要是血清蛋白。蛋白质冠现象的一个显著后果是,最初设计用于将纳米药物导向体内环境中特定细胞或器官的靶向配体意外丢失。mRNA 纳米医学对特定细胞和组织靶向递送有很高的要求,以便将 mRNA 分子有效地递送到靶细胞中,在那里它们可以发挥最大的治疗效果。在这篇综述中,我们专注于递送系统和组织特异性应用,旨在为纳米医学领域提供当前纳米-生物相互作用的流行和仍然神秘的范例,这是靶向 mRNA 递送追求中的一个艰巨障碍。我们还阐明了 mRNA 治疗中目前面临的障碍,并通过考虑前瞻性途径——要么调节冠层,要么采用“从敌人到盟友”的方法——旨在为推进 mRNA 纳米医学指明方向。